PRCM
ALNY icon

Pine River Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pine River Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,619
Closed -$254K – 609
2014
Q4 		$254K Buy
+2,619
New +$243K ﹤0.01% 649

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pine River Capital Management's ALNY Position: Q1 2015 in Review

Pine River Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2015, closing a stake of 2,619 shares — an estimated $254K sold.

Pine River Capital Management first reported a position in ALNY in Q4 2014 and held it in 1 quarter. The position peaked at $254K in Q4 2014. 238 funds tracked by Wall St. Rank hold ALNY as of Q1 2015.

  • Pine River Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Pine River Capital Management sold 2,619 Alnylam Pharmaceuticals shares in Q1 2015, an estimated $254K.
  • Pine River Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Pine River Capital Management's Alnylam Pharmaceuticals position peaked at $254K in Q4 2014.
  • 238 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2015.

Based on Pine River Capital Management's 13F filing for Q1 2015, filed 15 May 2015.